UiPath, Inc. (NYSE:PATH - Get Free Report) has been given an average rating of "Hold" by the seventeen ratings firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $13.1786.
Several research firms have recently weighed in on PATH. Evercore ISI increased their price objective on UiPath from $11.00 to $15.00 and gave the company an "in-line" rating in a report on Friday, May 30th. Barclays restated an "equal weight" rating on shares of UiPath in a research note on Friday, May 30th. Wells Fargo & Company restated an "equal weight" rating on shares of UiPath in a research note on Friday, May 30th. Morgan Stanley upped their price target on UiPath from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research note on Monday, June 2nd. Finally, Scotiabank upped their price target on UiPath from $12.00 to $13.00 and gave the stock a "sector perform" rating in a research note on Friday, May 30th.
View Our Latest Analysis on PATH
Insider Buying and Selling at UiPath
In other UiPath news, CFO Ashim Gupta sold 56,322 shares of the stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $12.72, for a total value of $716,415.84. Following the completion of the transaction, the chief financial officer owned 859,991 shares in the company, valued at approximately $10,939,085.52. This represents a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel Dines sold 45,000 shares of the stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $12.43, for a total value of $559,350.00. Following the completion of the transaction, the chief executive officer owned 5,058,376 shares of the company's stock, valued at $62,875,613.68. The trade was a 0.88% decrease in their position. The disclosure for this sale can be found here. Insiders sold 876,310 shares of company stock valued at $10,969,372 in the last quarter. 23.19% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the business. Twin Peaks Wealth Advisors LLC purchased a new position in UiPath in the second quarter worth $28,000. AdvisorNet Financial Inc raised its position in UiPath by 320.4% in the second quarter. AdvisorNet Financial Inc now owns 2,476 shares of the company's stock worth $32,000 after acquiring an additional 1,887 shares in the last quarter. Versant Capital Management Inc increased its position in shares of UiPath by 198.6% in the first quarter. Versant Capital Management Inc now owns 2,962 shares of the company's stock valued at $31,000 after buying an additional 1,970 shares in the last quarter. GAMMA Investing LLC increased its position in shares of UiPath by 48.0% in the second quarter. GAMMA Investing LLC now owns 2,989 shares of the company's stock valued at $38,000 after buying an additional 969 shares in the last quarter. Finally, IFP Advisors Inc increased its position in shares of UiPath by 508.0% in the second quarter. IFP Advisors Inc now owns 3,283 shares of the company's stock valued at $42,000 after buying an additional 2,743 shares in the last quarter. Hedge funds and other institutional investors own 62.50% of the company's stock.
UiPath Trading Up 1.8%
PATH stock opened at $11.60 on Tuesday. The company has a market capitalization of $6.16 billion, a P/E ratio of 386.67, a PEG ratio of 4.36 and a beta of 1.02. UiPath has a twelve month low of $9.38 and a twelve month high of $15.93. The business has a 50 day simple moving average of $11.60 and a 200-day simple moving average of $11.76.
UiPath (NYSE:PATH - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $361.73 million during the quarter, compared to the consensus estimate of $347.36 million. UiPath had a return on equity of 1.28% and a net margin of 1.35%.The company's revenue was up 14.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.04 earnings per share. UiPath has set its FY 2026 guidance at EPS. Q3 2026 guidance at EPS. Research analysts predict that UiPath will post -0.17 EPS for the current fiscal year.
UiPath Company Profile
(
Get Free Report)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UiPath, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.
While UiPath currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.